See more : Tokai Carbon Korea Co., Ltd. (064760.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINCU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nitcho Corporation (2961.T) Income Statement Analysis – Financial Results
- Jiumaojiu International Holdings Limited (9922.HK) Income Statement Analysis – Financial Results
- The Nature Holdings Co., Ltd. (298540.KQ) Income Statement Analysis – Financial Results
- Magazine Luiza S.A. (MGLUY) Income Statement Analysis – Financial Results
- ISS A/S (ISSDY) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINCU)
Industry: Biotechnology
Sector: Healthcare
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 28.97M | 52.15M | 40.08M | 7.12M | 0.00 |
General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Source: https://incomestatements.info
Category: Stock Reports